End Ot Helium

Embed Size (px)

Citation preview

  • 7/30/2019 End Ot Helium

    1/31

    VASCULAR ENDOTHELIUM &

    ITSFUNCTIONAL ASSESSMENT

    Upa KukongviriyapanDepartment of Physiology, Faculty of Medicine

    Khon Kaen University, Thailand.

    B.Sc. Experimental Pathology

    Queen Marys School of Medicine and Dentistry

    The Royal London HospitalOctober 12, 2005

  • 7/30/2019 End Ot Helium

    2/31

    Topic Contents

    Structure and functions of vascularendothelial cell.

    The endothelial dysfunction.

    The oxidant- stress induced endothelial

    dysfunction.

    How to assess endothelial functions. Summary

  • 7/30/2019 End Ot Helium

    3/31

    The Normal Vascular Endothelium

    Historically viewed as a passivevascular lining.

  • 7/30/2019 End Ot Helium

    4/31

    Vascular Endothelium

    Many important roles to maintain vascular homeostasis:

    Vascular tone regulation

    VSMC proliferation

    Inflammatory responses

    Haemostasis

    It produces and releases vasoactive, thromboregulatory

    and growth factor substances.

  • 7/30/2019 End Ot Helium

    5/31

    Tousoulis, et al., Heart 2005; 91: 353-358.

    Endothelial cell functions

    Maintaining the vascular tone: Vasodilation and Vasoconstriction

  • 7/30/2019 End Ot Helium

    6/31

    Functional targets Physiological action/Mediators

    Growth Stimulation Inhibition

    PDGF, FGF NO, PGI2, TGF

    IGF-1, ET, AII

    Endothelial cell functions

    Inflammation Proinflammatory AntiinflammatoryAdhesion molecules

    Selectin-E, VCAM-1, ICAM-1, PECAM-1

  • 7/30/2019 End Ot Helium

    7/31

    Functional targets Physiological action/Mediators

    Haemostasis Prothrombotic Antithrombotic

    PAI-1 PGI2, TPA

    Endothelial cell functions

    Calles-Escandon and Cipolla, Endocrine Rev 2001; 22: 36-52.

  • 7/30/2019 End Ot Helium

    8/31

    Factors affecting vascular tone and structure

  • 7/30/2019 End Ot Helium

    9/31

    - pathological conditions

    - altered anticoagulant &

    anti-inflammatory properties

    - impaired modulation of

    vascular growth &

    dysregulation of vascular

    remodeling

    An impairment of endothelium-dependent vasorelaxationcaused by a loss of NO bioactivity in the vessel wall.

  • 7/30/2019 End Ot Helium

    10/31

  • 7/30/2019 End Ot Helium

    11/31

  • 7/30/2019 End Ot Helium

    12/31

    Unifying model: Endothelial dysfunction to CVD

    Xanthine oxidase, NADP/NADPH oxidase

    uncoulpled eNOS

    NO bioavailability

  • 7/30/2019 End Ot Helium

    13/31

    How can we assess the

    endothelial function?

  • 7/30/2019 End Ot Helium

    14/31

    Methods for exploring endothelial function.(Guerci et al., Diabetes Metab 2001; 27: 425-434.)

  • 7/30/2019 End Ot Helium

    15/31

    Clinical Studies Supporting the Prognostic Value ofEndothelial Vasomotor Function Testing.(Ganz, et al. Circulation 2003; 108: 2049-2053.)

    Patients with endothelial dysfunction had a far greater incidence of adverse

    cardiovascular events in follow-up compared with patients with preserved

    endothelial function.

  • 7/30/2019 End Ot Helium

    16/31

    Key points for evaluating ED.

    Tousoulis D, et al., Heart 2005; 91: 353-358.

  • 7/30/2019 End Ot Helium

    17/31

    Evaluating Endothelial Function in Humans

    Non-invasive techniques

    High resolution ultrasonography: Assessment of

    flow-mediated dilatation (FMD). Strain-gauge plethysmography: Evaluation of

    forearm blood flow (FBF).

  • 7/30/2019 End Ot Helium

    18/31

    Flow-mediated dilatation (FMD)Is defined as an endothelium-

    dependent process that reflects therelaxation of a conduit artery whenexposed to increased flow and,thereby, increased shear stress.An impaired FMD response reflectsendothelial dysfunction.A temporary increase in shear stresscan be induced by increasing the localblood flow, the so-calledre

    active hyperemia.

    An abrupt decrease in vascularresistance mediated by the EDNOcaused FMD.

    Tousoulis D, et al., Heart 2005: 91: 553-558.

  • 7/30/2019 End Ot Helium

    19/31

    The genesis of FMD

    Moens, et al., Chest 2005; 127: 2254-2263.

  • 7/30/2019 End Ot Helium

    20/31

    Flow-mediated vasodilation (FMD)

  • 7/30/2019 End Ot Helium

    21/31

    Equipment: Ultrasonic imaging of

    brachial artery diameter

    Measurement of vasodilation response by

    ultrasonic imaging of arterial diameter: should be equipped

    with vascular software

    for 2D imaging, colorand spectral Doppler, an

    internal ECG monitor

    and high frequency

    vascular transducer

    attached to a high-quality

    mainframe ultrasound.and

    Noninvasive, simple, costly, widely available, need further

    validation.

  • 7/30/2019 End Ot Helium

    22/31

    Brachial Artery Flow-Mediated Dilation

    Baseline 5 Minutes Post-Occlusion

    Blood Pressure Cuff

    Occlusion 1 Minute

    Release

    3.1 mm 3.6 mm

  • 7/30/2019 End Ot Helium

    23/31

    Forearm blood flow

    (Strain-gauge plethysmography)

    Noninvasive, simple, reproducible and less observerdependent, need further validation.

    The strain-gauge is attached to the upper forearm, andconnected to plethysmographic device.

    .

    FBF is measured by temporarily occluding the venousreturn (by a cuff inflated to 40 mmHg) and measuredthe slight swelling of the distal portion of the limb dueto continued arterial inflow.

    d f

  • 7/30/2019 End Ot Helium

    24/31

    The initial rate of swellingrepresents the arterial inflow.

    The technique evaluates the

    percentage change of flowfrom baseline to themaximum flow duringreactive hyperaemia following

    a five minute ischaemia of theforearm.

    Forearm blood flow

    (Strain-gauge plethysmography)

    Tousoulis D, et al., Heart 2005: 91: 553-558.

  • 7/30/2019 End Ot Helium

    25/31

    Sample window

    The FBF is estimated by the gradient of the tangent to the curveduringthe first cardiac cycles.

    Result of forearm flow is expressed as ml/100 ml tiss/min or thepercent changes in flow.

  • 7/30/2019 End Ot Helium

    26/31

    Timetable of FMD & FBF

    Tousoulis D, et al., Heart 2005; 91: 353-358.

  • 7/30/2019 End Ot Helium

    27/31

    Application in clinical trials

    Study design:Acute or long-term intervention trials.Sample size:A crossover or a parallel- group design study.

    Methodology:Select most reproducible results.

    Evaluating precision of the technique.

    Individual trainingin the principles and technical

    aspect of Doppler ultrasonography and Strain-gaugeplethysmography.

  • 7/30/2019 End Ot Helium

    28/31

    SUMMARY

    Endothelial functional testing can be used as anindicator for vascular damage or vascular disease and also

    other diseases relating to oxidative stress conditions.

    Reversal of endothelial dysfunction protects against

    progression of vascular disease.

  • 7/30/2019 End Ot Helium

    29/31

    Proposed new tests for evaluating endothelial functionshould be developed with optimal characteristics;

    Cost-effective, reproducible and standardization.

    Ability to predict risk and relationship to establishedtests of risk.

    Useful as a screen for drug development.

    Can identify individual patients.

    Can predict a reduction in the risk of clinical events.

    SUMMARY

  • 7/30/2019 End Ot Helium

    30/31

    QUESTIONS

    What are the main functions of the vascular endothelial

    cell?

    What is the endothelial dysfunction? How can it lead tothe cardiovascular disease?

    How can we evaluate the endothelial functions?

    What are the key points for evaluating the

    endothelial dysfunction?

  • 7/30/2019 End Ot Helium

    31/31

    The End For Now

    But there is much more to learn!!!!

    Thank you!